SS-31
A mitochondria-targeted cardiolipin-stabilizing tetrapeptide FDA-approved in September 2025 as Forzinity for Barth syndrome — the first approved mitochondria-targeted peptide — with a Phase 3 trial ongoing in dry AMD and a new pivotal trial being planned in POLG-related mitochondrial myopathy.
SS-31 and elamipretide are two names for the same four-amino-acid peptide, which sticks to cardiolipin — a fat found only in the inner membrane of mitochondria — and helps the energy machinery there hold its shape. In September 2025 the FDA approved it as Forzinity for Barth syndrome, a very rare inherited disease, making it the first mitochondria-targeted peptide ever approved. That approval is narrow and conditional. The same drug has failed its main goal in heart failure, in a heart-attack trial, and in a mid-stage eye-disease trial, and there are no controlled trials in healthy people, so the anti-aging reputation is borrowed from the mechanism rather than earned in trials.
What is SS-31?
SS-31 (elamipretide) is a synthetic tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane. It received FDA accelerated approval in September 2025 under the brand name Forzinity for improving muscle strength in Barth syndrome patients weighing ≥30 kg — making it the first cardiolipin-directed mitochondrial therapeutic and the first mitochondria-targeted peptide ever approved. A Phase 3 trial continues in dry age-related macular degeneration (ReNEW, primary completion estimated August 2027). The Phase 3 NuPower trial (SPIMD-301) in primary mitochondrial disease from nuclear-DNA mutations finished in 2024, and the developer is now planning a new pivotal trial limited to POLG-related mitochondrial myopathy.
What SS-31 Is Investigated For
SS-31 (elamipretide) is investigated across Barth syndrome, primary mitochondrial myopathy, heart failure with reduced ejection fraction, dry age-related macular degeneration, ischemia-reperfusion injury, and broader mitochondrial-dysfunction indications. The strongest evidence — and the only approved indication — is Barth syndrome, a rare X-linked cardiolipin-metabolism disorder where the mechanistic case is unusually direct and long-term open-label extension data supports durable benefit. The honest caveats are substantial: Phase 2 trials in heart failure (PROGRESS-HF), acute MI (EMBRACE-STEMI), and dry AMD (ReCLAIM-2) missed their primary endpoints, and MMPOWER-3 in primary mitochondrial myopathy missed its primary with only genotype-specific post-hoc signals. No controlled trials exist for healthy-aging or general longevity use, research-chemical SS-31 is not equivalent to clinical-grade elamipretide, and strong mechanism — cardiolipin stabilization on the inner mitochondrial membrane — has not translated into broad clinical efficacy outside the one rare disease where the biology aligned most directly.
History & Discovery
SS-31 emerged from work by Hazel Szeto and Peter Schiller in the late 1990s and early 2000s on small peptides designed to penetrate cell membranes and concentrate inside mitochondria. Originally developed at Cornell as one of the 'Szeto-Schiller' (SS) series of mitochondrially targeted peptides, SS-31 (chemically D-Arg-2',6'-Dmt-Lys-Phe-NH2) was distinguished by its ability to selectively bind cardiolipin on the inner mitochondrial membrane without depending on a membrane potential — solving a problem that had limited earlier mitochondria-targeting strategies. The drug was licensed and developed by Stealth BioTherapeutics under the names Bendavia, MTP-131, and ultimately elamipretide. Stealth advanced the molecule through trials across multiple indications: ischemia-reperfusion injury after acute myocardial infarction (EMBRACE-STEMI, which missed its primary endpoint), heart failure with reduced ejection fraction (PROGRESS-HF, also negative), primary mitochondrial myopathy (MMPOWER-3, missed primary but suggested signals in subgroups), Barth syndrome (TAZPOWER and natural-history comparisons, ultimately supporting approval), and dry age-related macular degeneration (ReCLAIM trials). The regulatory journey included FDA Complete Response Letters, accelerated-approval discussions, and persistent debate about the right endpoints for ultra-rare mitochondrial diseases. Approval for Barth syndrome — a rare X-linked cardiolipin-metabolism disorder where the mechanistic case for elamipretide is unusually direct — represents the most clinically mature landing point for a mitochondria-targeted peptide to date. On September 19, 2025, the FDA granted accelerated approval to elamipretide hydrochloride under the brand name Forzinity for improving muscle strength in adult and pediatric Barth syndrome patients weighing ≥30 kg, making it the first approved cardiolipin-directed mitochondrial therapeutic. Commercial supply began in late November 2025, and AnovoRx, the exclusive US specialty pharmacy, began filling prescriptions in December 2025. The confirmatory trial required under the accelerated-approval pathway, the placebo-controlled Phase 3b/4 4TAZPower study (NCT07531251), began in July 2026. The company's next target is narrower than before. Its Phase 3 NuPower trial (SPIMD-301) in primary mitochondrial disease from nuclear-DNA mutations finished in 2024, and the company reports a genotype-dependent response in the POLG1 subgroup. After meeting the FDA in April 2026, Stealth (which began operating as Mighty Therapeutics in June 2026) said it would submit a synopsis for a new pivotal trial in POLG-related myopathy in the second half of 2026.
How It Works
SS-31 concentrates in the powerhouses of your cells (mitochondria) and helps stabilize the structures that produce cellular energy. By improving mitochondrial efficiency, it may support heart function, exercise capacity, and cellular health.
SS-31 selectively targets cardiolipin on the inner mitochondrial membrane. Cardiolipin is essential for the organization and function of electron transport chain complexes. By stabilizing cardiolipin, SS-31 optimizes electron transfer, reduces reactive oxygen species (ROS) production, and improves ATP synthesis efficiency. It also prevents cardiolipin peroxidation, which is a key event in mitochondrial dysfunction.
Evidence Snapshot
Human Clinical Evidence
Moderate. FDA accelerated approval for Barth syndrome (September 2025, Forzinity brand) based on TAZPOWER and natural-history comparison data, with the confirmatory Phase 3b/4 trial (4TAZPower, NCT07531251, n=48) recruiting since July 2026 and primary completion not estimated until September 2029. Phase 3 ongoing in dry AMD (ReNEW, NCT06373731, primary completion estimated August 2027). Earlier heart failure (PROGRESS-HF), acute MI (EMBRACE-STEMI), and mitochondrial myopathy (MMPOWER-3) trials missed primary endpoints.
Animal / Preclinical
Strong. Extensive animal data on mitochondrial protection and cardiac function.
Mechanistic Rationale
Very strong. Cardiolipin biology and mitochondrial bioenergetics are well characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about SS-31:
- 01Heart failure and AMD efficacy — trials in heart failure with reduced ejection fraction (PROGRESS-HF) and dry AMD (the Phase 2 ReCLAIM-2) failed to meet primary endpoints; the Phase 3 ReNEW trial in dry AMD (NCT06373731, n=313) is active and no longer recruiting, with primary completion estimated for August 2027 — the next major data point. Whether subgroups benefit and whether different dosing strategies might succeed in heart failure remains unresolved.
- 02Primary mitochondrial myopathy — MMPOWER-3 missed its primary endpoint, with genotype-specific post-hoc signals. Stealth then ran the Phase 3 NuPower trial (SPIMD-301) in primary mitochondrial disease from nuclear-DNA mutations, which finished in 2024; full results have not been posted on ClinicalTrials.gov. The company says NuPower supports a narrower focus on POLG1-mutation patients, and as of April 2026 it was preparing a synopsis for a new pivotal trial in POLG-related myopathy to discuss with the FDA. That intention has not yet become a trial: as of November 2026 no POLG-specific elamipretide study is registered on ClinicalTrials.gov, and NuPower’s own results are still not posted there two years after the trial completed. Whether this more homogeneous population will produce a positive pivotal remains to be seen.
- 03Long-term safety in chronic use — Barth syndrome open-label extension data is the longest continuous human exposure dataset, but this is a small population, and long-term safety in larger populations is not characterized.
- 04Healthy-aging or longevity use — there are still no controlled trials of elamipretide in healthy adults for general mitochondrial support or anti-aging endpoints, and extrapolation from rare-disease data is not justified. The nearest thing now underway is SHAPE (NCT07275424), an open-label, single-arm Phase 2a pilot run by a University of Washington investigator in 30 adults aged 65 to 80 with low aerobic capacity, dosing daily for four weeks. Because it is single-arm and unblinded it cannot answer the efficacy question — with no control group, any change it measures could be practice effects, regression to the mean, or expectation — but it is the first registered study to ask about this population at all.
- 05Optimal route and formulation — daily subcutaneous injection has been the standard; an oral or longer-acting formulation has not reached late-stage development.
- 06Cardiolipin-targeting selectivity in vivo — while in vitro and animal mechanism is well characterized, tissue-level selectivity and downstream consequences in long-term human use are still being mapped.
Forms & Administration
For its one approved use, elamipretide is no longer a trial-only drug. Forzinity is supplied as a 280 mg/3.5 mL (80 mg/mL) single-patient-use vial, four to a carton, kept refrigerated at 2–8 °C and discarded eight days after first opening. The labeled dose for Barth syndrome patients weighing at least 30 kg is 40 mg — a 0.5 mL injection — subcutaneously once daily at the same time each day, into the abdomen at least two inches from the navel or into the outer thigh, rotating the site daily. The label permits adult patients or caregivers to inject at home after proper training, if a clinician judges that appropriate and with medical follow-up. The commercial route runs from a Barth syndrome prescription through the manufacturer patient-support program to a specialty pharmacy; it is not a retail or compounding product. For every indication other than Barth syndrome — mitochondrial myopathy, heart failure, dry AMD, and anything in the longevity bucket — enrollment in a registered trial remains the only legitimate route of access. SS-31 sold under research-chemical labeling is a different thing entirely from the approved product. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
The approved Forzinity dose for Barth syndrome is 40 mg subcutaneously once daily in patients weighing at least 30 kg, which matches the dose carried through the clinical program; earlier studies tested a 4–60 mg range. The label carries one dose modification: in adults with an estimated glomerular filtration rate below 30 mL/min who are not on dialysis, the dose drops to 20 mg once daily. There is explicitly insufficient information to recommend a dose for adults with an eGFR below 30 who are on dialysis, or for pediatric patients at or above 30 kg who have renal impairment. There is no recognized off-label SS-31 dose for general 'mitochondrial support' or anti-aging in healthy adults.
Frequency
Once-daily subcutaneous injection is the standard schedule used across the elamipretide clinical program.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
In approved and trial settings the drug is used continuously, with periodic clinical reassessment, rather than cycled. Long-term open-label extensions in Barth syndrome have followed patients for several years on continuous therapy.
Protocol Notes
Where elamipretide is approved, it is supplied through a manufacturer-controlled specialty pharmacy network, not through general retail or compounding pharmacies. SS-31 sold under research-chemical labeling is not equivalent to the clinical product in identity, purity, or sterility assurance, and should not be assumed to behave the same way. Any patient considering SS-31 for an unapproved indication, including general longevity use, is operating outside the evidence base of the elamipretide clinical program.
Dosing for SS-31/elamipretide outside its approved indication is not supported by clinical trial data. The numbers above describe what has been studied, not a recommendation for off-label use.
Timeline of Effects
Onset
Acute pharmacodynamic effects on mitochondrial ATP production have been measured within hours of a single elamipretide dose in older-adult skeletal muscle (using in vivo phosphorus MRS). Clinical functional endpoints in trials — six-minute walk distance, cardiac function, fatigue scores — typically emerge over weeks to months of daily dosing.
Peak Effect
Functional improvements in published trials (Barth cardiomyopathy, mitochondrial myopathy subgroups) typically continued to evolve across 12–24 weeks of daily dosing and beyond, suggesting the response curve reflects gradual mitochondrial remodeling rather than acute receptor pharmacology.
After Discontinuation
In Barth syndrome open-label extension data, clinical worsening has been observed in some patients after discontinuation, consistent with a disease-modifying rather than purely symptomatic effect. Pharmacokinetic clearance of elamipretide itself is on the order of hours, so persistent benefit reflects mitochondrial-membrane and cellular adaptation rather than continued drug presence.
Monitoring & Measurement
Bloodwork & Labs
- •Complete blood count with differential, specifically absolute eosinophil count — the label reports eosinophil counts rising frequently once dosing runs 30 days or longer, peaking around day 90 and settling back over 6 to 12 months
- •Absolute neutrophil count — not a drug effect, but neutropenia is a core feature of Barth syndrome itself and is tracked throughout care
- •Estimated glomerular filtration rate — this is the one measurement that changes the dose, since an eGFR below 30 mL/min without dialysis moves the daily dose from 40 mg to 20 mg
- •Creatine kinase and a basic metabolic panel — standard supportive monitoring in mitochondrial disease rather than anything specific to this drug
Functional & Performance Tests
- •Knee extensor muscle strength — the intermediate endpoint the accelerated approval was granted on, and the measure most directly tied to the labeled claim
- •Six-minute walk distance — the functional endpoint used across the elamipretide trial program and part of the confirmatory trial composite
- •Five-times sit-to-stand and timed up-and-go — the other two components of the confirmatory trial composite score
- •Echocardiography — Barth syndrome cardiomyopathy is monitored on its own schedule by the treating cardiologist
- •Injection-site inspection — site reactions affected every patient on drug in the approval dataset, so this is the most likely day-to-day finding
When to Test
Driven by the treating specialist centre rather than by a generic schedule. Functional measures were assessed at 12-week intervals across the trial program; the confirmatory trial runs its composite from baseline to week 72.
Interpretation & Notes
This section describes monitoring for the one approved use — Barth syndrome, under specialist care — and it is not a protocol anyone should run on themselves. Two points are worth separating. The eosinophil rise is a genuine labeled observation, but in the trial data it was not accompanied by clinical symptoms or by changes in other laboratory values, and it resolved on continued dosing; it is something to recognize rather than something to react to. The kidney measurement matters differently, because it is the only input that changes the dose. Everything else on this list is really monitoring of Barth syndrome rather than of the drug. For any unapproved use there is no monitoring consensus to describe, because there is no established dose, no established benefit, and no trial population to generalize from.
Common Questions
Is SS-31 FDA approved?
For one rare disease, yes. The FDA granted accelerated approval on 19 September 2025 for Forzinity (elamipretide hydrochloride) to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. That is the entire approved indication. It is not approved for heart failure, mitochondrial myopathy generally, macular degeneration, fatigue, or aging. Accelerated approval also means the evidence rested on an intermediate measure — knee-extensor strength — and that continued approval depends on a confirmatory trial, which only began recruiting in July 2026 and is not expected to finish until 2029.
What is the difference between SS-31, elamipretide, Bendavia and Forzinity?
They are all the same molecule at different stages of its life. SS-31 is the original laboratory name from the Szeto-Schiller peptide series at Cornell. MTP-131 and Bendavia were development code and trade names used by Stealth BioTherapeutics. Elamipretide is the international non-proprietary name, and Forzinity is the US brand name under which it was approved in 2025. The important distinction is not between these names but between the approved GMP product and powder sold as research-chemical SS-31, which is a different thing in every way that matters.
Does SS-31 work for anti-aging or fatigue?
There is no trial evidence that it does, and the honest summary is that the idea rests on mechanism plus one short study. A randomized study did show that a single dose measurably improved in vivo mitochondrial ATP production in the skeletal muscle of older adults — a real finding, but acute physiology in a small group, not a demonstration that daily dosing produces more energy, better endurance, or a longer life. The first registered study in healthy older adults, a 30-person open-label pilot called SHAPE, began in late 2025; because it has no control group it cannot settle the question either. Meanwhile the drug has missed its primary endpoint in heart failure, acute myocardial infarction, and Phase 2 dry AMD, which is a useful reminder that an elegant mechanism does not reliably become a clinical effect.
How is Forzinity dosed?
For patients weighing at least 30 kg the labeled dose is 40 mg injected under the skin once daily, at the same time each day, into the abdomen at least two inches from the navel or into the outer thigh, rotating the site. There is one labeled adjustment: adults with an estimated glomerular filtration rate below 30 mL/min who are not on dialysis take 20 mg daily instead. The label states there is not enough information to recommend a dose for people on dialysis, or for children at or above 30 kg who have kidney impairment. Vials are refrigerated and discarded eight days after first opening.
Why did elamipretide fail in heart failure and macular degeneration?
No single explanation is established, and the trials failed in different ways. PROGRESS-HF in heart failure with reduced ejection fraction and EMBRACE-STEMI in acute myocardial infarction both missed their primary endpoints, as did the Phase 2 ReCLAIM-2 trial in dry AMD. The plausible readings are that mitochondrial dysfunction is one contributor among many in these common diseases rather than the root cause as it is in Barth syndrome, that the endpoints and durations were not matched to a slow mitochondrial remodeling effect, or that tissue-level drug exposure was insufficient. The Phase 3 ReNEW trial in dry AMD is still running and has a primary completion date estimated for August 2027, so the eye question is not yet closed.
Is research-chemical SS-31 the same as the approved drug?
No, and the gap is larger than usual here. Forzinity is made under pharmaceutical manufacturing controls with verified identity, purity, sterility and stability, supplied in preserved single-patient vials through a specialty pharmacy. Powder sold as research-chemical SS-31 carries none of those assurances; the actual peptide content, the contamination profile and the biological activity are all unverified. Anyone reasoning from the clinical trial literature to a research-chemical vial is assuming an equivalence nobody has tested.
Is SS-31 banned in sport?
The molecule is not named on the WADA Prohibited List, on the 2026 list or the 2027 list that takes effect on 1 January 2027. Because the FDA approved it for human therapeutic use in September 2025, the S0 category for non-approved substances no longer captures the molecule either. That describes the molecule, not the product: SS-31 sold for research use has unverified identity and may be contaminated with something that is prohibited, so an athlete should clear any elamipretide or SS-31 product with their anti-doping organization first.
Who SS-31 Is NOT For
- •Pregnancy — limited human pregnancy safety data; rare-disease use during pregnancy should be evaluated case by case with a specialist.
- •Breastfeeding — transfer into breast milk and effects on nursing infants are not well characterized.
- •Pediatric use outside an approved indication — pediatric dosing has been studied in Barth syndrome trials but not in healthy or unrelated populations.
- •Known hypersensitivity to elamipretide or to excipients in the formulation, including injection-site reactions severe enough to preclude continued use.
- •Use of research-chemical SS-31 in any clinical context — the unregulated supply chain makes identity, purity, and sterility unverifiable, which is unacceptable for any patient population.
Drug & Supplement Interactions
Elamipretide has a relatively limited published drug-interaction profile, in part because it is given subcutaneously and largely cleared by peptidase-mediated degradation rather than CYP-mediated metabolism. No major CYP-based interactions have been highlighted in regulatory documents. Clinical-trial protocols typically allowed concurrent standard-of-care therapies for the underlying disease (heart-failure medications in PROGRESS-HF, mitochondrial-disease supportive care in MMPOWER-3 and TAZPOWER), without signals of clinically meaningful interaction. Patients with Barth syndrome are commonly on cardiac medications (beta-blockers, ACE inhibitors), and these have been used alongside elamipretide in trials. For patients considering SS-31 for unapproved indications, the lack of comprehensive interaction data outside the rare-disease populations studied is a significant gap. Disclosure to all prescribing clinicians is appropriate given the absence of broader pharmacology data.
Safety Profile
Common Side Effects
Cautions
- • Forzinity contains benzyl alcohol (20 mg per mL) and is not approved for use in neonates — benzyl alcohol has caused fatal gasping syndrome and metabolic acidosis in low-birth-weight and preterm neonates given it intravenously; the product is also not approved for intravenous use
- • Serious hypersensitivity reactions are a labeled warning, and the label notes they may occur within minutes to months after treatment initiation, so vigilance is required throughout treatment, not only at first dose
- • The approval safety database is very small — 12 male patients aged 12 to 35, eleven of them Caucasian — so the adverse-event picture outside that group is genuinely unknown
- • Approved only for Barth syndrome (≥30 kg) in the US; all other uses remain off-label or investigational
- • Accelerated approval is conditional on a confirmatory post-marketing trial
- • Research-chemical SS-31 does not carry the identity, purity, or sterility assurances of GMP-manufactured Forzinity
What We Don't Know
Long-term safety in populations outside Barth syndrome is not yet characterized. Efficacy in heart failure (PROGRESS-HF failed), dry AMD (ReNEW ongoing), and primary mitochondrial myopathy (MMPOWER-3 mixed) remains unresolved.
Legal Status
United States
Elamipretide hydrochloride received FDA accelerated approval on September 19, 2025 under the brand name Forzinity, indicated for improving muscle strength in adult and pediatric Barth syndrome patients weighing ≥30 kg — the first approval of a mitochondria-targeted peptide and the first therapy for this ultra-rare genetic disease. Approval was based on knee-extensor strength data from the TAZPOWER trial supplemented by natural-history comparisons, and a confirmatory post-marketing trial is required under the accelerated pathway. Distribution is through AnovoRx as the exclusive US specialty pharmacy. Forzinity is not approved for primary mitochondrial myopathy generally, heart failure, dry AMD, or other indications studied in trials, several of which produced negative or mixed results. Off-label SS-31 use through compounding or research-chemical channels is not equivalent to the approved GMP product and is not supported by FDA review.
International
As of November 2026 the FDA accelerated approval is the only elamipretide marketing authorization this page can document from a primary source. We were unable to confirm the drug’s European status directly — the EMA medicine and search endpoints returned errors rather than a record — so we make no claim either way about an EU authorization, CHMP opinion or orphan designation. Patients outside the United States should check with a national rare-disease specialty centre or their own regulator rather than assuming US approval travels.
Sports & Competition
Elamipretide (SS-31) is not named on the WADA Prohibited List, either on the 2026 list or on the 2027 list that takes effect on 1 January 2027. Because the FDA approved it for human therapeutic use in September 2025, WADA's S0 class for non-approved substances no longer applies to the molecule, and no other section of the List covers it. That status describes the molecule, not research-chemical products: SS-31 sold 'for research use' has unverified identity and purity and may be contaminated, so athletes should check with their anti-doping organization before using any SS-31 or elamipretide product.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
SS-31 is an approved general anti-aging drug.
Reality
Elamipretide is FDA-approved as Forzinity (September 2025) only for improving muscle strength in Barth syndrome patients ≥30 kg — an ultra-rare cardiolipin-metabolism disease. It is not approved for general aging, sarcopenia, longevity, or heart failure indications, several of which have failed in trials. The approved indication is narrow and the off-label leap is substantial.
Myth
All SS-31 sold as a research chemical is equivalent to the elamipretide used in clinical trials.
Reality
Clinical-grade elamipretide is manufactured under GMP, with controlled identity, purity, sterility, and stability. Research-chemical SS-31 has none of those guarantees and may differ in actual peptide content, contamination profile, and biological activity.
Myth
Because the mechanism is elegant, the clinical results have been uniformly positive.
Reality
The mechanism — cardiolipin stabilization on the inner mitochondrial membrane — is genuinely well characterized and conceptually compelling. The clinical record is more mixed: positive enough in Barth syndrome to support approval, negative in heart failure and in the Phase 2 dry AMD trial, and mixed in primary mitochondrial myopathy. Strong mechanism does not guarantee broad clinical efficacy.
Myth
SS-31 directly increases ATP production in healthy people.
Reality
Acute single-dose work in older adults has measured improvements in skeletal-muscle ATP synthesis, but those are short-term physiology studies, not evidence that healthy individuals will gain durable energy or performance benefits from chronic dosing. The effect size and clinical meaning in healthy populations are not established.
Published Research
36 studiesReport from the 2026 Barth Syndrome Foundation International Scientific, Medical & Family Conference: Advances in Barth Syndrome Research, Therapy Development, and Clinical Care
The first Barth Syndrome Foundation conference held after the approval, and the best single snapshot of where the program now stands: the post-approval confirmatory study, ABHD18 emerging as a second cardiolipin-pathway target, and the sponsor operating as Mighty Therapeutics.
Mitochondria-targeted peptide elamipretide alleviates cisplatin-induced ovarian failure by activating the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway
Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats
Cardiolipin remodelling in mitochondrial therapeutics: translational evidence chains from elamipretide to emerging strategies (Front Physiol, 2026)
Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model (Circ Heart Fail, 2026)
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function (Chem Biol Drug Des, 2026)
Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury (Neurochem Int, 2026)
Elamipretide: First Approval
The Drugs journal first-approval monograph — the standard reference summarizing the development history, pharmacology and regulatory basis of the September 2025 Barth syndrome accelerated approval.
Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial
The post-hoc analysis that produced the genotype hypothesis now driving the company’s plans — signals concentrated in nuclear-DNA, and specifically POLG, mutation carriers. Post-hoc subgroup findings from a failed primary endpoint are hypothesis-generating, not confirmatory.
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
The 168-week open-label extension supplying the durability evidence for the Barth syndrome approval, and the longest continuous human exposure dataset that exists for any mitochondria-targeted peptide.
Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction
Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial
Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
The largest randomized elamipretide trial and a clear negative: MMPOWER-3 missed its primary endpoints in primary mitochondrial myopathy. It is the single strongest piece of evidence against generalizing the Barth syndrome result to mitochondrial disease at large.
Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data
Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome
SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease
Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration
Targeting mitochondrial dysfunction with elamipretide
Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid
Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease
In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
The one piece of human data that the longevity interest actually rests on: a single dose measurably raised in vivo mitochondrial ATP production in older adults’ skeletal muscle. It is acute physiology in a small sample, not evidence of durable functional benefit from chronic dosing.
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism
TAZPOWER, the pivotal trial behind the 2025 accelerated approval. A 12-week placebo-controlled crossover in 12 patients did not separate on its primary endpoints; the open-label extension that followed is where the knee-extensor strength gains emerged, which is why the approval rests on an intermediate endpoint plus natural-history comparison rather than on the randomized phase.
A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial
PROGRESS-HF missed its primary endpoint in heart failure with reduced ejection fraction, closing what had been the molecule’s largest commercial opportunity and a major reason the program narrowed to rare disease.
Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice
Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
Treatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice
Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide
Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis
The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction
Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia
Potent mitochondria-targeted peptides reduce myocardial infarction in rats
Popular Stacks Including SS-31
Quick Facts
- Class
- Mitochondrial Peptide
- Tier
- C
- Evidence
- Moderate
- Safety
- Moderate Data
- Updated
- Nov 2026
- Citations
- 36PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.